Lancet

• Latest
• Best
• Search…

• Lancet · Nov 2023

  Letter

  Gaza is facing a humanitarian catastrophe.

  no abstract available

  expand abstract… or not…

• Lancet · Nov 2023

  Comment Letter

  Classifying necrotising mpox as an AIDS-defining condition - Authors' reply.

  no abstract available

  read more… or not…

• Lancet · Nov 2023

  Letter

  A decolonised Commission agenda: the missing ingredients.

  no abstract available

  expand abstract… or just mark as read…

• Lancet · Nov 2023

  Comment Letter

  AATD as a genetic risk factor for aneurysmal disease - Authors' reply.

  no abstract available

  expand abstract… or just mark as read…

• Lancet · Nov 2023

  Randomized Controlled Trial

  Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.

  ONWARDS 6 compared the efficacy and safety of once-weekly subcutaneous insulin icodec (icodec) and once-daily insulin degludec (degludec) in adults with type 1 diabetes. ⋯ Novo Nordisk.

  explore further… mark as read…